Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT03485547Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 2 years. Started Aug 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT03485547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485547.